Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 4;49(4):e12919. doi: 10.1111/nan.12919

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

p62‐positive astrocytes in CuATSM treatment group. p62‐immunoreactive astrocytes were observed in the motor cortex of ALS‐TDP (A: Case #3) and ALS‐SOD1 (B: Case #1) cases that had received CuATSM but not in ALS‐TDP (C: Case #11) or ALS‐SOD1 (D: Case #8) cases that had not received CuATSM treatment. The p62‐positive astrocytes were of similar appearance to GFAP‐positive astrocytic morphology (E: Case #3, F: Case #1). pTDP‐positive astrocytes were not seen in ALS‐TDP (G: Case #3) and ALS‐SOD1 (H: Case #1) cases. Immunofluorescent triple labelling demonstrated co‐localisation of p62, GFAP and SOD1 in the p62‐immunopositive astrocytes (I–M). A and C inset scale is 50 μm.